CASI Entered into a Sublicense Agreement with Tianshi for CID-103 to Treat Autoimmune Diseases
Shots:
- CASI to receive a $10M up front, milestones along with royalty. Tianshi will complete its first equity financing then CASI will hold 15% of Tianshi’s equity at $3M through its wholly-owned PRC subsidiary upon completion of equity investment. Tianshi to receive $17.98M from 2 venture capital investors
- Tianshi gets an exclusive license globally for CID-103 in autoimmune diseases & disorders in humans while CASI will retain exclusive commercialization & co-marketing rights to CID-103 in the same indication along with all revenue generated in the US. In China, CASI owns co-commercial rights to CID-103 for autoimmune-derived hematology & oncology
- CID-103 has higher preclinical safety & activity against cancers that express CD38 compared to other CD38 mAbs
Ref: CASI | Image: CASI
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
